Hill­house Cap­i­tal en­dors­es Chi­na-based Hai­He Bio­phar­ma's can­cer pipeline in $146M round

Count Hai­He Bio­phar­ma in the new gen­er­a­tion of Chi­nese biotechs an­swer­ing the clar­i­on call for home­grown in­no­va­tion.

The Shang­hai-based drug­mak­er is emerg­ing from rel­a­tive ob­scu­ri­ty with a $146 mil­lion round and the sup­port of some big names in Chi­na’s bio­phar­ma in­dus­try, in­clud­ing Hill­house Cap­i­tal, CSPC Phar­ma as well as the ven­ture arm of the Chi­nese Acad­e­my of Sci­ence. PE firm Hua­gai led the round, which al­so in­volved a siz­able group of in­vestors, such as On­co­Cap­i­tal and Yingke PE.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER